Medications used to treat MS have all been developed relatively recently, are still, which means that the majority of them are still patent protected. Until these patents expire, no generics can be manufactured and brand name medications are the only option. As the patents for these extremely expensive medications expire, more and more generic options will become available and the treatment landscape will undoubtedly change. We have already seen this happen with Copaxone, which is manufactured by Teva. There are currently multiple generic versions of the Glatiramer Acetate injection available, and insurers have made many patients switch off Copaxone on onto generics. A generic version of Ampyra, a medication used to increase walking speed and lower extremity strength, will also be available shortly. Since we will be seeing more and more generic options, I wanted to take a look at the differences between brand and generic medications, and how they will impact MS treatment.